Specific Cytotoxicity of Targeted 177Lu and 212Pb-Based Radiopharmaceuticals.
Bull Exp Biol Med
; 171(5): 627-632, 2021 Sep.
Article
em En
| MEDLINE
| ID: mdl-34626281
ABSTRACT
Two radiopharmaceutical preparations were developed on the basis of artificial targeted polypeptide ZHER2 specific to HER2/neu tumor marker and radionuclides 177Lu (ZHER2-HSA-chelator-177Lu) or 212Pb (ZHER2-HSA-chelator-212Pb). The objective was to evaluate in vitro the cytotoxic activity of the targeted radiopharmaceuticals using two cultured human breast cancer cell lines with different expression of HER2/neu SK-BR3 (high expression of HER2/neu) and MCF-7 (low expression of HER2/neu). It was shown that the cytotoxic effect of both preparations was significantly higher against the SK-BR-3 cells. The cytotoxicity correlated with the incubation period (it was higher after 72 h than after 24 h) and was significantly more pronounced in comparison with activity of radionuclide salts without a specific ligand. In vivo preclinical study of these pharmaceuticals seems to be very promising in animals with xenografted tumors showing high expression of HER2/neu marker.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Radioisótopos
/
Neoplasias da Mama
/
Radioisótopos de Chumbo
/
Imunotoxinas
/
Lutécio
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Federação Russa